Microsatellite instability in colorectal cancer

Microsatellite instability in colorectal cancer Background. Colorectal cancer (CRC) is the third most common cancer in the world. In 75% CRC develops sporadically, in 25% hereditary or as a consequence of inflammatory bowel disease. CRC carcinogenesis develops over many years. The cause of CRC in 85% is chromosomal instability (CIN) and in 15% microsatellite instability (MSI-H), where hereditary nonpolyposis colorectal cancer (HNPCC) represents 10-20%. Microsatellite sequences (MS) are repeated sequences of short stretches of DNA all over the genome. Microsatellite stability (MSS) means MS are the same in each cell of an individual, whereas microsatellite instability (MSI-H) means MS differ in normal and cancer cells of an individual. The cause of MSI-H is a damaged mismatch repair mechanism (MMR), with the most important MMR proteins being MSH2, MLH1 and MSH6. Conclusions. MSI-H seems to be an important prognostic factor in CRC and an important predictive factor of CRC chemotherapeutic treatment efficacy. Clinical trials conducted until now have shown contradictory findings in different chemotherapeutic settings, adjuvant and palliative; therefore MSI-H is going to be the object of the future research. The future of cancer treatment is in the individualized therapy based on molecular characteristics of the tumour, such as MSI-H in CRC.

[1]  A. Feinberg,et al.  Concerted nonsyntenic allelic loss in human colorectal carcinoma. , 1988, Science.

[2]  C. Boland,et al.  Loss of DNA mismatch repair in acquired resistance to cisplatin. , 1996, Cancer research.

[3]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[4]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.

[5]  P. Hsieh,et al.  DNA mismatch repair: Molecular mechanism, cancer, and ageing , 2008, Mechanisms of Ageing and Development.

[6]  P. Modrich,et al.  Mechanisms and biological effects of mismatch repair. , 1991, Annual review of genetics.

[7]  L. Boardman,et al.  Genetic testing for young-onset colorectal cancer: case report and evidence-based clinical guidelines , 2010, Radiology and oncology.

[8]  B. Leggett,et al.  Colorectal cancer: molecular features and clinical opportunities. , 2010, The Clinical biochemist. Reviews.

[9]  F. Bazzoli,et al.  High Thymidylate Synthase Expression in Colorectal Cancer with Microsatellite Instability: Implications for Chemotherapeutic Strategies , 2005, Clinical Cancer Research.

[10]  W. Curran,et al.  Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. , 2004, Anticancer research.

[11]  A. Duval,et al.  Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. , 2002, Cancer research.

[12]  D. Sargent,et al.  Model‐based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients , 2010, Cancer.

[13]  N. Claij,et al.  Microsatellite instability in human cancer: a prognostic marker for chemotherapy? , 1999, Experimental cell research.

[14]  E. Van Cutsem,et al.  Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Radman,et al.  Missing mismatch repair , 1993, Nature.

[16]  J. Lynch,et al.  The genetic pathogenesis of colorectal cancer. , 2002, Hematology/oncology clinics of North America.

[17]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[18]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Ducreux,et al.  Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. , 2003, Cancer research.

[20]  B. Uzzan,et al.  Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. , 2009, Anticancer research.

[21]  M. Guo,et al.  Epigenetic changes in colorectal cancer , 2013, Chinese journal of cancer.

[22]  H. Shay,et al.  The duodenal mechanism in the control of gastric motility; intraluminal gastric and duodenal pressure studies. , 1956, Gastroenterology.

[23]  J. Cubiella,et al.  Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer , 2005, Gut.

[24]  T. Kunkel,et al.  The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. , 1998, Cancer research.

[25]  A. Poullis,et al.  Apoptosis in the Colonic Crypt, Colorectal Adenomata, and Manipulation by Chemoprevention , 2009, Cancer Epidemiology Biomarkers & Prevention.

[26]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[27]  Bert Vogelstein,et al.  Gatekeepers and caretakers , 1997, Nature.

[28]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[29]  D. Rao,et al.  Prokaryotic DNA mismatch repair. , 2006, Progress in nucleic acid research and molecular biology.

[30]  M. Parmar,et al.  Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Leggett,et al.  Emerging concepts in colorectal neoplasia. , 2002, Gastroenterology.

[32]  K. Kinzler,et al.  Genetic instability in colorectal cancers , 1997, Nature.

[33]  B. Dutrillaux,et al.  Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status , 2000, British Journal of Cancer.

[34]  S. Kozuka,et al.  Premalignancy of the mucosal polyp in the large intestine: II. Estimation of the periods required for malignant transformation of mucosal polyps , 1975, Diseases of the colon and rectum.

[35]  A. Jung,et al.  Pathologische Diagnostik für die individualisierte Therapie des Dickdarmkarzinoms , 2010, Der Pathologe.

[36]  M. Radman,et al.  Carcinogenesis. Missing mismatch repair. , 1993, Nature.

[37]  E. Dogliotti,et al.  Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. , 2010, European journal of cancer.

[38]  N. Petrelli,et al.  The onset and extent of genomic instability in sporadic colorectal tumor progression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Richard D Kolodner,et al.  The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. , 2004, Gastroenterology.

[40]  A. de la Chapelle,et al.  Clinical relevance of microsatellite instability in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Bert Vogelstein,et al.  APC mutations occur early during colorectal tumorigenesis , 1992, Nature.

[42]  S. SenGupta,et al.  The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[43]  Amanda G Paulovich,et al.  When Checkpoints Fail , 1997, Cell.

[44]  King-Jen Chang,et al.  High‐frequency microsatellite instability predicts better chemosensitivity to high‐dose 5‐fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection , 2002, International journal of cancer.

[45]  B. Uzzan,et al.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. , 2009, European journal of cancer.

[46]  J. Warusavitarne,et al.  The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer , 2007, International Journal of Colorectal Disease.

[47]  D. Shibata,et al.  Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation , 1994, Nature Genetics.

[48]  J. Cucherousset,et al.  Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. , 2007, Anticancer research.

[49]  L. Aaltonen,et al.  Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. , 2000, Gastroenterology.

[50]  E. E. Gresch.  Genetic Alterations During Colorectal-Tumor Development , 1989 .

[51]  V. Velenik.  Post-treatment surveillance in colorectal cancer , 2010, Radiology and oncology.

[52]  W. Grady.  Genomic instability and colon cancer , 2004, Cancer and Metastasis Reviews.

[53]  Seung-Yong Jeong,et al.  Prognostic significance of microsatellite instability in sporadic colorectal cancer , 2004, International Journal of Colorectal Disease.

[54]  J. Cubiella,et al.  The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. , 2009, European journal of cancer.

[55]  T. Kunkel,et al.  The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases , 2008, Cell Research.

[56]  S. Bull,et al.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.

[57]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[58]  S. Aebi,et al.  The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.

[59]  Y. Niv.  Microsatellite instability and MLH1 promoter hypermethylation in colorectal cancer. , 2007, World journal of gastroenterology.

[60]  J. Eshleman,et al.  Mismatch repair defects in human carcinogenesis. , 1996, Human molecular genetics.

[61]  S. Aebi,et al.  The role of DNA mismatch repair in drug resistance. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  C. Boland,et al.  Cellular effects of CPT‐11 on colon carcinoma cells: Dependence on p53 and hMLH1 status , 2002, International journal of cancer.

[63]  P. Modrich,et al.  DNA mismatch repair: functions and mechanisms. , 2006, Chemical reviews.

[64]  J. Ocvirk.  Advances in the treatment of metastatic colorectal carcinoma , 2009 .

[65]  C. Boland,et al.  Mismatch repair proficiency and in vitro response to 5-fluorouracil. , 1999, Gastroenterology.

[66]  K. Kinzler,et al.  Clues to the pathogenesis of familial colorectal cancer. , 1993, Science.

[67]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[68]  C. Tartaglia,et al.  Nutritional modulation of the inflammatory response in inflammatory bowel disease--from the molecular to the integrative to the clinical. , 2007, World Journal of Gastroenterology.

[69]  Ajay Goel,et al.  Microsatellite instability in colorectal cancer. , 2010, Gastroenterology.

[70]  K. Baerenfaller,et al.  5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. , 2007, Gastroenterology.

[71]  P. Quirke,et al.  Prediction of the response of colorectal cancer to systemic therapy. , 2002, The Lancet. Oncology.